The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells
© The Author(s). 2018
Received: 8 August 2017
Accepted: 19 February 2018
Published: 6 March 2018
Tumor hypoxia is an independent prognostic factor associated with poor patient survival. Emerging evidence suggests that hypoxia can potentially maintain or enhance the stem cell phenotype of both normal stem cells and cancer cells. However, it remains to be determined whether cell fate is regulated in vivo by the hypoxic tumor microenvironment (TME).
We established a hypoxia-sensing xenograft model to identify hypoxic tumor cell in vivo primarily using human breast cancer cell lines MDA-MB-231 and MCF7. Hypoxic tumor cells were identified in situ by fluorescence of green fluorescence protein. They were further isolated from xenografts, purified and sorted by flow cytometry for detailed analysis of their stem cell characteristics.
We have found that hypoxic tumor cells freshly isolated from xenografts contain increased subpopulations of tumor cells with cancer stem cell (CSC)-like characteristics. The CSC characteristics of the hypoxic tumor cells are further enhanced upon re-implantation in vivo, whereas secondary xenografts derived from the non-hypoxic tumor cells remain similar to the primary xenografts. Interestingly, the phenotypes exhibited by the hypoxic tumor cells are stable and remain distinctively different from those of the non-hypoxic tumor cells isolated from the same tumor mass even when they are maintained under the same ambient culture conditions. Mechanistically, the PI3K/AKT pathway is strongly potentiated in the hypoxic tumor cells and is required to maintain the CSC-like phenotype. Importantly, the differential cell fates between hypoxic and non-hypoxic tumor cells are only found in tumor cells isolated from the hypoxic TME in vivo and are not seen in tumor cells treated by hypoxia in vitro alone.
These previously unknown observations suggest that the hypoxic TME may promote malignant progression and therapy resistance by coordinating induction, selection and/or preferential maintenance of the CSC-like phenotype in tumor cells.
Tumor hypoxia, a hallmark of tumor microenvironment (TME), is an independent prognostic factor for advanced disease progression and poor patient survival [1–3]. As an emerging paradigm, hypoxia has the potential to regulate cell fate and differentiation, especially the cellular properties associated with stem cells [4–8]. These observations provide important insights into the role of TME in the regulation of malignant tumor progression from the perspective of cancer stem cells (CSCs). CSCs are defined as a distinct subpopulation of tumor cells with unlimited self-renewal and tumor-initiating potential [9, 10]. Current studies have shown that CSCs are likely to be the major cause of therapy resistance and tumor recurrence [9, 11]. Similar to normal stem cells, maintenance and differentiation of CSCs are also subject to regulation by both genetic and environmental or niche factors [10, 12–14]. Studies have shown that the hypoxic TME is strongly associated with increased cancer cell “stemness”. In clinical tumor specimens, tumor cells located in hypoxic regions appear poorly differentiated and express stem-cell-associated genes [15, 16]. Poorly differentiated pancreatic cancer cells show strong nuclear accumulation of hypoxia-inducible factor 1α (HIF-1α) protein . Higher HIF-α protein levels are also found in the stemcell-like tumor cells in neuroblastomas [18, 19] or gliomas . When maintained under in vitro hypoxic conditions, tumor cells exhibit enhanced clonogenicity [21–23] and can activate an embryonic stem cell-like transcription program in a HIF-dependent manner . Recent studies using three-dimensional culture systems have reported hypoxia-associated cell-type plasticity  and CSC heterogeneity . These data suggest that tumor hypoxia is likely to have a direct and strong impact on the fate of cancer cells, especially CSCs. However, it remains to be clearly determined whether the CSC fate is differentially regulated by the hypoxic TME in vivo.
In this study, we have developed a hypoxia-sensing xenograft model using human breast cancer cell lines and have made several new discoveries with regard to cell fate determination by the hypoxic TME. First, we have obtained direct evidence that the CSC-like subpopulation is significantly enriched in the enhanced green fluorescent protein (EGFP)+ hypoxic population. Second, the CSC characteristics continue to be enhanced upon re-implantation of the EGFP+ hypoxic cells, suggesting the CSC-like properties displayed by the hypoxic tumor cells are stable and continue to be enriched. Consistently, the phenotypes exhibited by the EGFP+ hypoxic tumor cells remain stably distinct from those of the EGFP− non-hypoxic tumor cells isolated from the same tumor mass even when they are maintained under the same ambient culture condition. Third, the PI3K/AKT pathway is strongly potentiated in the EGFP+ hypoxic tumor cells and is required to maintain the CSC-like phenotype. Interestingly, the cell fate differences between hypoxic and non-hypoxic tumor cells are found only in the tumor cells isolated from the hypoxic TME in vivo, but not in tumor cells treated by hypoxia in vitro alone. These previously unrecognized observations suggest that tumor hypoxia may promote malignant progression and therapy resistance by differential selection for and/or maintenance of the CSC-like tumor cells in the hypoxic TME.
Generation of the hypoxia-sensing cell lines
MDA-MB-231 and MCF7 human breast cancer cells (American Type Culture Collection (ATCC)) were transfected with 5HRE/GFP plasmid (a gift from Martin Brown and Thomas Foster, Addgene plasmid # 46926)  and selected with 500 μg/ml of G418. For positive selection, cells were incubated at 1% O2 in a hypoxia chamber (Invivo 400) for 24 h and EGFP+ cells were collected by flow cytometry. For negative selection, the sorted EGFP+ cells were then incubated under normal tissue culture conditions and EGFP− cells were sorted by flow cytometry. Three rounds of positive and negative selections were used to establish the hypoxia-sensing cell lines. All cell lines are authenticated using the short tandem repeat (STR) method.
MDA-MB-231/HRE-EGFP and MCF7/HRE-EGFP cells were mixed with growth factor-depleted Matrigel (1:1) and then injected either orthotopically into the mammary fat pads or ectopically under the skin in the upper back of female athymic mice (6–7 weeks of age) at a concentration of 1–2 × 106 cells per injection site. For tumor takeandgrowth curve analysis, 10 × 103 cells were injected per site. When the tumor size reached approximately 800 mm3, tumors were excised for isolation of tumor cells.
Tumor cell dissociation and purification
Excised xenograft tumors were minced and incubated at 37 °C for 2 h in a dissociation medium containing 10% fetal calf serum, 0.5 U/ml dispase (07913, STEMCELL Technologies), 5 mg/ml Collagenase Type IV (CLS-4, Worthington Biochemical), and 100 U/ml penicillin streptomycin. Red blood cells were removed by incubation with a red blood cell lysis buffer containing 0.8% NH4Cl for 10 min on ice. Host mouse cells were depleted using a Mouse Cell Depletion Kit (130–104-694, Miltenyi Biotec.)
Analysis of cell surface marker by flow cytometry
All antibodies used for flow cytometry were purchased from eBiosciences (ThermoScientific). For CD24 and CD44 double stain, anti-CD24-PE-Cyanine 7 (1:20, #25–0247-42) and anti-CD44-eFlour 450 (1:50, #48–0441-82) were used with mouse IgGκ-PE-Cyanine 7 (1:20, #25–4714-42) and rat IgG2b-eFlour 450 as IgG controls (1:50, #48–4031). For CD44 and CD49f double stain, anti-CD44-eFlour 450 (1:50) and anti-CD49f-PE-Cyanine 7 (1:20, #25–0495-82) were used with rat IgG2b-eFlour 450 and mouse IgGκ-PE-Cyanine 7 as IgG controls. For human epithelial cell adhesion molecule (EPCAM) stain, anti-CD326-PE-Cyanine 7 (1:20, #25–9326-41) was used with mouse IgGκ-PE-Cyanine 7 as IgG control. The BD LSR II flow cytometer was used for fluorescence-activated cell sorting (FACS). The instruments were calibrated daily. FACS data were analyzed using the FlowJo™ software.
Flow-assisted cell sorting
Human tumor cells were isolated from xenografts and separated from the host mouse cells. After filtration through a 40-μm cell strainer, tumor cells were then sorted into the hypoxic (EGFP+, approximately the top 30%) and non-hypoxic (EGFP−, approximately the bottom 30%) fractions using the BD FACSAria™ II.
Cells were suspended at 1 × 106 cells/ml in pre-warmed Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) with 2% fetal calf serum (FCS) and 10 mM HEPES buffer. Hoechst 33342 (ThermoScientific) was added at a final concentration of 5 μg/ml in the presence or absence of verapamil hydrochloride (50 μM, Sigma-Aldrich). After incubation at 37 °C for 90 min, cells were washed with ice-cold FACS buffer containing 3% FCS and 10 mM HEPES, resuspended in the FACS buffer, and filtered through a 40-μm cell strainer. Propidium iodide was added at a final concentration of 2 μg/ml before FACS to gate viable cells. FACS analyses were done using the LSRII (BD Bioscience). The Hoechst 33342 dye was excited at 350 nm and its fluorescence was dual-wavelength analyzed (blue, 440 nm; red, 650–670 nm).
Detection of hypoxic regions in xenografts
Hypoxyprobe™-1 (pimonidazole HCl, Hypoxyprobe, Inc) was injected intraperitoneally 2 h before xenograft tumor isolation at a dose of 60 mg/kg bodyweight. Tumors were excised, fixed in formalin, and cryopreserved in optimum cutting temperature compound (OCT). Tumor sections (7 μm thick) were incubated with anti-pimonidazole rabbit IgG1 antibody (PAB2627AP, Hypoxyprobe, Inc.) and then a fluorescently labeled anti-rabbit IgG antibody. Nuclei were counter stained with Hoechst 33342. The fluorescence stains were examined under a fluorescence microscope (Zeiss ZX10 Imager M2).
The clonogenic assay is based on our previously published protocols [22, 28]. Briefly, tumor cells were plated at 600 cells/well for MDA-MB-231 cells and at 1000 cells/well for MCF7 cells in 6-well plates and incubated for 10 to 14 days. Colonies were stained with crystal violet. Plating efficiency (PE) = numbers of colonies (≥50 cells/colony) divided by numbers of cells plated × 100%.
Tumor sphere formation assay
The tumor sphere formation assay has been described in our previous publication . Briefly, tumor cells were incubated as a single-cell suspension in a tumor sphere medium containing DMEM-F12, 3:1 (Invitrogen), 2% B27 supplement, 40 ng/ml basic fibroblast growth factor (bFGF), and 20 ng/ml epidermal growth factor (EGF), and plated into tissue culture dishes pre-coated with polyhydroxyethylmethacrylate (polyHEMA, Sigma-Aldrich). After incubation for 4 to 6 days, the numbers of tumor spheres were counted under a microscope.
Tumor cell invasion assay
Invasion of tumor cells was determined using trans-well chambers with polycarbonate membranes of 8-μm pore size according to the manufacturer’s instructions. The dividing membranes were pre-coated with 50 μl 15% Matrigel solution in serum-free medium. Freshly sorted tumor cells isolated from xenograft tumors were suspended in a culture medium containing 0.5% FBS and loaded (10 × 103 cells per well) into the upper chamber of the trans-well plates. The lower chambers were filled with a culture medium containing 10% fetal bovine serum (FBS). After incubation for 48 h, cells migrating to the underside of the membrane were stained with Diff-Quik™ Stain Set (B4132-1A, Siemens) and cells remaining on the upper surface of the membrane were removed with a cotton swab. The number of migrated cells on each membrane was counted in 20 random fields at ×200 magnification under a light microscope.
Wound healing assay
Tumor cells were allowed to grow to 100% confluence in 60-mm dishes. Wound tracks were created by manually scraping the cell monolayer with a P1000 pipet tip. After incubation for 12 and 24 h, the gap filling was examined under a light microscope. Wound healing is quantitatively shown as percent gap fill.
Western blot analysis
Antibodies to the following antigens were used for western blots: phospho-AKT-S473 (#4060, 1:5000, Cell Signaling), total AKT (#4691, 1:5000, Cell Signaling), phospho-ERK1/2-T202/T204 (#4377, 1:10,000, Cell Signaling), total ERK1/2 (#9102, 1:10,000, Cell Signaling), phospho-PI3Kp85 (#4228, 1:1000, Cell Signaling), phospho-mTOR-S2448 (#5536, 1:1000, Cell Signaling), HIF-1α (#14179, 1:1000, Cell Signaling), HIF-2α (#NB100–122, 1:1000, Novus Biologicals), β-actin (#A5316, 1:10,000, Sigma Aldrich), and vinculin (ab18058, 1:10,000, Abcam). Protein bands were visualized using ECL substrates (ThermoFisher Scientific, #34080) and imaged using the Kodak X-OMAT 2000A.
Real-time quantitative reverse transcription PCR (RT-qPCR)
Total cellular RNA was isolated with the TRizol reagent (Invitrogen). First-strand cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). RT-qPCR was performed on StepOne Plus (Applied Biosystems) using iTaq Universal SYBR Green Supermix (Bio-Rad) under the following conditions: initiation at 95 °C × 30 s, 40 cycles at 95 °C × 15 s, and 60 °C × 60 s. The housekeeping gene HPRT was used as a control for normalization. Specificity of the primers was confirmed by a single peak on the dissociation curve. For CD44, TGCCGCTTTGCAGGTGTAT (forward) and GGCCTCCGTCCGAGAGA (reverse); for CD24, AAACAACAACTGGAACTTCAAGTAACTC (forward) and GGTGGTGGCATTAGTTGGATTT (reverse); for GLUT1, GATTGGCTCCTTCTCTGTGG (forward) and TCAAAGGACTTGCCCAGTTT (reverse); for LOX1, GAACACAGGAACATCATCCTG (forward) and ACGCAGCACAGTCCTTGGTT (reverse); for HPRT, TATGGCGACCCGCAGCCCT (forward) and CATCTCGAGCAAGACGTTCAG (reverse).
Global gene expression analysis
Total cellular RNA was isolated with RNeasy® Mini Kit (74,104, Qiagen) and treated with DNase I for 10 min. Global gene expression profile analysis was done using Affymetrix HTA microarrays at the Yale Center for Genomic Analysis. The hybridization patterns and signal intensities were analyzed and interpreted using the Affymetrix GeneChip Expression Console.
Microarray data were analyzed using analysis of variance (ANOVA) by Yale Center for Analytical Sciences (YCAS). Two-group comparisons were analyzed using the two-tailed Student’s t test (GraphPad Prizm 7). A significant difference was declared if the p value was < 0.05.
The cancer stem cell-like population of tumor cells is enriched in the hypoxic TME in vivo
The cell fate regulation of tumor cells by the TME is critical for understanding clonal heterogeneity and malignant progression but remains to be fully investigated. We have established two hypoxia-sensing tumor models by stably expressing a hypoxia-responsive transcription enhancer element (five tandem repeats of HRE or 5XHRE)-driven destabilized d2EGFP construct  in human breast cancer cell line MDA-MB-231 and MCF7, respectively. These two cell lines represent the two most common types of breast cancer, i.e. the basal type (MDA-MB-231) and the luminal type (MCF7). The HRE-EGFP reporter gene is transcriptionally activated by hypoxia-inducible transcription factor (HIF)-1 and/or HIF-2 . Similar strategies have been used in other tumor models [30, 31] to identify hypoxic cells. We generated the hypoxia-reporter cell lines using three rounds of negative and positive selection to ensure low background under normoxic conditions and robust induction of EGFP under hypoxic conditions (Additional file 1). We also confirmed that HIF accumulation occurring during hypoxia treatment is readily reversible in the ambient air in the sorted ex vivo tumor cells from xenografts generated by our hypoxia-sensing cancer cell lines (Additional file 2, panel A).
We next purified the human tumor cells from xenografts (Additional file 3) and separated the EGFP+ and EGFP− cells by flow cytometry (Fig. 1c). Consistent with the literature , the basal-like MDA-MB-231 cell-derived xenografts contained a larger hypoxic population than the xenografts derived from the luminal-like MCF7 cells (Fig. 1c). Using global gene expression analysis, we found that a panel of commonly observed hypoxia-inducible genes [33–35], including BNIP3L, EGLN3, LOXL4 and P4HA1, were significantly upregulated in the EGFP+ MDA-MB-231 tumor cells, compared to the EGFP− cells (Fig. 1d). Collectively, these data demonstrate that these HRE-EGFP-modified breast cancer cell lines can serve as a reliable hypoxia-sensing model to identify hypoxic tumor cells in xenografts.
Among other CSC markers, we found the expression of the CSC marker CD133 and aldehyde dehydrogenase (ALDH) activity were not significantly different in MDA-MB-231 cells isolated from different tumor microenvironments (data not shown), suggesting the hypoxic TME exerts specific effects on the CD44/CD24 pathways. Interestingly, hypoxia in vitro does not significantly affect the CD24+ cell population (Fig. 2c). These findings underscore the unique ability of hypoxic TME in vivo to enhance and/or maintain the CSC phenotype, which cannot be recapitulated simply by exposure to hypoxia in vitro.
In contrast to the basal-like MDA-MB-231 cell-derived tumors, the hypoxic TME had a different impact on the cell fate of the luminal-like MCF7-derived xenografts. The non-hypoxic (EGFP−) MCF7 cells exoko vivo had very low levels of CD44 (Fig. 2d, e). However, there was a significant increase in the numbers of the CD44+ cells in the hypoxic (EGFP+) MCF7 tumor cell population with the predominant increase of the CD44+/CD24+ population (Fig. 2d, e). Interestingly, it has been shown that the CD24+ MCF7 cells exhibit higher proliferation and stronger invasion than their CD24− counterparts . Clinically, CD24 overexpression is significantly associated with unfavorable outcomes in patients with luminal A breast cancers  or with breast tumors of intermediate-grade differentiation . Furthermore, the CD44+/CD49f+ population is also strongly increased among the hypoxic (EGFP+) MCF7 tumor cells (Fig. 2f). Our data suggest that the CSC-like population of the luminal-type MCF7 cells are likely to be characterized by the CD44+/CD24+ phenotype, which is strongly enhanced in the hypoxic TME. Collectively, these data provide direct ex vivo evidence demonstrating enrichment of the CSC-like breast tumor cells in the hypoxic TME.
The ex vivo hypoxic tumor cells possess aggressive CSC-like properties
The ex vivo hypoxic MDA-MB-231 tumor cells also demonstrated strong invasion and migration. In contrast to non-hypoxic tumor cells, we found that the freshly sorted EGFP+ hypoxic MDA-MB-231 tumor cells invaded more readily through the Matrigel barrier (Fig. 3b). Furthermore, the ex vivo EGFP+ hypoxic MDA-MB-231 tumor cells were capable of healing a wounded monolayer in cell culture much more rapidly and efficiently than their non-hypoxic counterparts (Fig. 3c). These data demonstrate that the ex vivo EGFP+ hypoxic tumor cells possess enhanced self-renewal and clonogenic potential and highly invasive characteristics.
We further examined the tumorigenic potential of the ex vivo hypoxic and non-hypoxic MDA-MB-231 tumor cells, respectively, by implanting the freshly sorted EGFP+ and EGFP− tumor cells in athymic mice. As shown in Fig. 3d, the ex vivo EGFP+ orthotopic tumor cells formed new xenografts at a tumor-take rate of 90% versus 40% for the EGFP− tumor cells. Similarly, the tumor-take rate was 60% for the freshly isolated EGFP+ subcutaneous tumor cells versus 20% for the EGFP− tumor cells. The secondary xenografts originating from the ex vivo EGFP+ orthotopic tumor cells also grew at a higher rate than did xenografts formed from the EGFP− tumor cells (Fig. 3d). These results demonstrate that the hypoxic TME can select tumor cells with biological properties associated with aggressive and CSC-like phenotypes, including enhanced self-renewal, pronounced invasiveness and robust tumor-initiating potential.
The CSC-like tumor cells are further enriched in the hypoxic TME upon sequential implantation in vivo
As shown in Fig. 4b, the difference in the CD24+ population is further increased between the 2nd xenografts derived from the 1st sorted EGFP+ tumor cells and those derived from 1st sorted EGFP− cells. In particular, the CD24+ population increased from approximately 13% (Fig. 2b) to approximately 25% (Fig. 4b) when the EGFP− MDA-MB-231 cells were re-implanted. Although both 2nd xenografts maintained high levels of CD44, the xenografts derived from the EGFP+ cells had slightly but significantly higher levels of CD44 than the EGFP− cell-derived xenografts (right arrow in the FACS histogram, Fig. 4c). The differential changes in cell surface expression of CD44 and CD24 are consistent with their differential gene expression between the two types of 2nd xenografts and between the 2nd and 1st xenografts (Fig. 4d and Additional file 5). Functionally, the 2nd xenograft tumor cells originating from the 1st sorted EGFP+ cells displayed significantly higher clonogenic potential than the 2nd xenograft tumor cells originating from the 1st sorted EGFP− cells and the unsorted tumors cells isolated from the 1st xenografts (Fig. 4e). Collectively, these data suggest that the EGFP− cells isolated from the non-hypoxic TME are likely to be more prone to differentiation whereas the EGFP+ hypoxic tumor cells continue to maintain their CSC-like cell fate and their aggressive properties.
The PI3K-AKT pathway is required for maintenance of the CD44+/CD24− CSC phenotype
Upon examination of several stem-cell-related signaling pathways, we found that PI3K/AKT pathway, a critical pathway involved in pro-survival and pro-stem-cell maintenance [48–52], was preferentially activated in the ex vivo hypoxia-selected breast cancer cells. We found that the 2nd xenograft tumor cells originating from the 1st EGFP+ MDA-MB-231 cells showed robust AKT S473 phosphorylation in response to serum stimulation, compared to the 2nd xenograft tumor cells originating from the 1st EGFP− cells (Additional file 6, panel A). Similar results were obtained from the 2nd xenograft tumor cells derived from 1st EGFP+ and EGFP− MCF7 cells (Additional file 6, panel B). Because the preferential AKT activation in the ex vivo hypoxic cells was stably maintained even under the ambient non-hypoxic conditions, these data suggest that these hypoxic breast cancer cells isolated ex vivo from xenografts may have acquired a distinct and stable phenotype compared to their neighboring non-hypoxic tumor cells.
The PI3K-AKT pathway is well-recognized as a key mechanism for regulating maintenance, proliferation and survival of both normal and cancer stem cells [53–55]. We examined whether the PI3K/AKT pathway plays an important role in the maintenance of the CSC-like phenotype of the ex vivo EGFP+ hypoxic tumor cells using LY294002, a specific PI3K inhibitor, to suppress AKT activation (Additional file 2, pannel B). After incubation with LY294002 for up to 5 days in vitro, both the xenograft-derived EGFP+ and EGFP− MDA-MB-231 cells showed progressive increases in the CD24+ population (Fig. 6e), indicating cell differentiation. Notably, the EGFP+ cells showed stronger upregulation of CD24. In contrast, CD44 expression was not significantly affected in either cell population (data not shown). The increase in the CD24+ population correlated with increased CD24 gene expression, whereas there were relatively small changes in CD44 gene expression (Fig. 6f). Although the EGFP+ tumor cells displayed robust mTOR phosphorylation, the mTOR inhibitor, rapamycin, did not strongly affect the CSC-associated CD24 and CD44 markers (data not shown). Collectively, these data suggest that the enhanced AKT activation is required for maintaining the CSC-like phenotype exhibited by the EGFP+ breast cancer cells isolated ex vivo from xenografts.
The hypoxia-dependent regulation of CSC-associated phenotypes and functions has been proposed and actively investigated [7, 39–41]. A number of in vitro studies have shown that hypoxia or hypoxia-sensing pathways play a significant role in the maintenance of the CSC phenotype in breast cancer cells [56–62]. Hypoxia is also implicated in increased CSC-like populations in breast cancer xenografts treated by antiangiogenic agents . However, definitive in vivo evidence has remained elusive. Herein, our data have provided direct evidence demonstrating that the hypoxic TME favors enrichment and/or maintenance of the CSC-like tumor cells in vivo.
In this study, we have established hypoxia-sensing xenograft models using the 5xHRE-driven d2EGFP reporter gene (HRE-EGFP)  in breast cancer cell lines. In the xenografts derived from these breast tumor cell lines, the EGFP+ tumor cells are primarily localized in the regions that are positively stained for pimonidazole, a widely used bioreductive marker of hypoxia. These results indicate that our HRE-EGFP-based xenograft models can reliably identify tumor cells that are hypoxic in the TME. Because the expression of d2EGFP (half-life ≅ 2 h) requires stabilized HIF-1α and/or HIF-2α, these models are best suited for identifying hypoxic tumor cells around the time of observation or analysis. Similar strategies have been used in other tumor models [30, 31] to identify hypoxic cells. Nonetheless, we cannot rule out the possibility that some tumor cells might express EGFP due to a condition of pseudohypoxia, i.e. stabilization of HIF-α without oxygen deficiency.
As shown by our combined in vitro and in vivo data, our xenograft model has the potential to identify hypoxic tumor cells at approximately ≤ 10 mmHg pO2 or ≤ 1.3% O2, which is well within the hypoxic range in human breast cancers clinically observed by direct pO2 measurement . However, identification and isolation of viable hypoxic breast cancer tumor cells in the clinics are extremely challenging, if possible at all. Nonetheless, a comprehensive approach using both genomics and proteomics could be employed to determine whether breast cancer stem cells are enriched in the hypoxic regions of clinical human breast cancers.
Different breast cancer cell lines express different sets of cancer stem cell markers, which may reflect their respective status of development or differentiation. Nonetheless, a number of studies have shown that CD44 expression is preferentially associated with the undifferentiated or progenitor-like phenotype whereas CD24 is expressed in more differentiated breast cancer cells with a luminal phenotype [65, 66]. MDA-MB-231 cells maintain high levels of CD44. Increased CD24 expression could signal differentiation. Our data indeed confirm that the CD44+/CD24− MDA-MB-231 cells exhibit stronger stem cell characteristics than their CD44+/CD24+ counterparts do. Therefore, we consider the CD44+/CD24− MDA-MB-231 cells as being more breast cancer stemcell-like. On the other hand, MCF7 cells are mainly CD44−/low/CD24+. Emergence of CD44+/CD24+ MCF7 cells, also positive for another stem cell marker CD49f, could result from increased stemcell-like populations in the hypoxic tumor microenvironment in vivo. Importantly, the ex vivo hypoxic tumor cells from both breast cancer xenograft models possess biological functions closely associated with CSC characteristics, including self-renewal and clonogenic potential, motility and invasion, and tumorigenicity. It is noteworthy that the enrichment of the CSC-like population occurs in the hypoxic TME in vivo only and exposure to hypoxia in vitro does not significantly affect cell fate. Consistent with this point of view, a comprehensive bioinformatics study  has shown that the hypoxia gene signatures obtained from various in vitro cell culture models have poor prognostic values when applied to large clinical datasets of breast cancer patients. In contrast, the patient tumor-derived hypoxia gene signatures have statistically significant prognostic values . These findings strongly suggest that the phenotype and cell fate of tumor cells located in the naturally hypoxic regions are likely to be determined collectively by multiple factors in the hypoxic TME in combination with O2 deficiency.
Interestingly, the CSC characteristics of the EGFP+ hypoxic cells, but not the EGFP− non-hypoxic cells, are further increased upon re-implantation. These observations suggest that tumor cells localized in the hypoxic TME might have acquired relatively stable phenotypes especially those closely associated with the CSC characteristics and that they continue to evolve upon re-implantation. Consistent with this new concept, we have found that the ex vivo EGFP+ hypoxic cells exhibit functionally distinct cell signaling pathways, including the PI3K/AKT pathway, from the EGFP− non-hypoxic cells even when they are maintained under the same ambient culture conditions. Although AKT activation in breast cancer cell lines has also been reported under in vitro hypoxic conditions , we have found in this study that hypoxia in vitro alone is not sufficient to alter these signaling pathways, suggesting the new cellular phenotype exhibited by the ex vivo EGFP+ hypoxic cells most likely results from complex regulations in the hypoxic TME. Nonetheless, these data strongly suggest that the hypoxic TME has the potential to cause tumor cells to evolve and to acquire new and stable properties that are distinct from those of tumor cells localized in the non-hypoxic TME within the same tumor mass. Consistent with these findings, it has recently been shown that the hypoxic TME can give rise to a subpopulation of tumor cells with a dormancy phenotype that is maintained even after dissemination .
As we have found, the ex vivo EGFP+ hypoxic cells show robust AKT activation in response to serum stimulation even under non-hypoxic conditions compared to the ex vivo EGFP− non-hypoxic cells that exhibit weak to moderate response. This unique phenotype has potentially significant biological implications because a similar situation of serum starvation-stimulation could be encountered in vivo. Hypoxic areas in solid tumors are often poorly perfused due to compromised blood flow and vascular malfunctions. Therefore, concentrations of serum-derived growth factors and other nutrients are expected to be much lower in the hypoxic areas than those in the well-perfused non-hypoxic regions. Serum stimulation occurs when a previously hypoxic area becomes re-oxygenated or when a hypoxic tumor cell invades locally into a non-hypoxic area or enters the bloodstream. The preferential activation of the PI3K/AKT pathway may confer significant survival and/or growth advantages on the previously hypoxic tumor cells during their invasion and metastasis.
We have further found that pharmacological inhibition of the PI3K/AKT pathway leads to strong increases in the CD24+ population of MDA-MB-231 cells, suggesting that activity of the PI3K/AKT pathway is essential for the maintenance of their CSC phenotype. In comparison to the ex vivo EGFP− cells, the CSC phenotype of the EGFP+ hypoxic cells is much more sensitive to inhibition of PI3K/AKT. This observation is consistent with the well-recognized role of the PI3K/AKT pathway in the maintenance of both normal and cancer stem cells [53–55]. Nonetheless, it is highly possible that other as yet unidentified stem-cell-related pathways may also be involved in cell fate determination by the hypoxic tumor microenvironment.
Cancer cell stemness, especially the capacity of self-renewal, is essential for enabling malignant progression and clonal evolution. In this study, we have provided direct evidence demonstrating that the hypoxic TME in vivo favors the enrichment and/or selection of the CSC-like characteristics. Importantly, the differential phenotypes of the tumor cells ex vivo from the hypoxic and non-hypoxic TME, respectively, are relatively stable even when they are subsequently maintained under normoxic ambient culture conditions, which suggests active clonal evolution and/or selection to yield a durable phenotype in the hypoxic TME in vivo.
In light of the findings that hypoxia occurs in human breast cancer  and is associated with poor treatment outcomes , the novel observations presented in this study strongly suggest that the hypoxic TME promotes malignant progression and confers resistance to therapy, at least in part, by inducing or sustaining the cancer stem cell phenotype.
The authors thank Dr Guilin Wang of Yale Center for Genomic Analysis (YCGA) for microarray analysis and Dr Xiaoqing Yu of Yale Center for Analytical Sciences (YCAS) for statistical analysis of microarray data.
This work is in part supported by a grant from CT Innovations (13-SCA-YALE-05 to ZY) and an NIH grant (R01 CA178254 to ZY). PGM is supported by R01 ES005775 from the NIH.
Availability of data and materials
The data involved in this study are available upon reasonable request.
HK, QL and ZY conceived and designed the study, and acquired data. All authors contributed to data analysis and manuscript preparation. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All animal procedures were reviewed and approved by the Institutional Animal Care & Use Committee (IACUC) of Yale University.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Semin Nucl Med. 2015;45(2):110–21.View ArticlePubMedGoogle Scholar
- Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–39.View ArticlePubMedGoogle Scholar
- Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56(19):4509–15.PubMedGoogle Scholar
- Lin Q, Yun Z. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol Ther. 2010;9(12):949–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol. 2008;9(4):285–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin Q, Lee YJ, Yun Z. Differentiation arrest by hypoxia. J Biol Chem. 2006;281(41):30678–83.View ArticlePubMedGoogle Scholar
- Yun Z, Lin Q. Hypoxia and regulation of cancer cell stemness. Adv Exp Med Biol. 2014;772:41–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010;7(2):150–61.View ArticlePubMedGoogle Scholar
- Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.View ArticlePubMedGoogle Scholar
- Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–91.View ArticlePubMedGoogle Scholar
- Liu C, Lin Q, Yun Z. Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity. Radiat Res. 2015;183(5):487–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbe DP, Gomez EC, Wang J, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Xin T, Greco V, Myung P. Hardwiring stem cell communication through tissue structure. Cell. 2016;164(6):1212–25.View ArticlePubMedPubMed CentralGoogle Scholar
- Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells. 2008;26(7):1818–30.View ArticlePubMedGoogle Scholar
- Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA. 2002;99(10):7021–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92(1):94–101.View ArticlePubMedGoogle Scholar
- Pietras A, Gisselsson D, Ora I, Noguera R, Beckman S, Navarro S, Pahlman S. High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol. 2008;214(4):482–8.View ArticlePubMedGoogle Scholar
- Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S, et al. HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA. 2009;106(39):16805–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Desplat V, Faucher JL, Mahon FX, Dello Sbarba P, Praloran V, Ivanovic Z. Hypoxia modifies proliferation and differentiation of CD34(+) CML cells. Stem Cells. 2002;20(4):347–54.View ArticlePubMedGoogle Scholar
- Kim Y, Lin Q, Zelterman D, Yun Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res. 2009;69(24):9271–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol. 1998;18(5):2845–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Mathieu J, Zhou W, Xing Y, Sperber H, Ferreccio A, Agoston Z, Kuppusamy KT, Moon RT, Ruohola-Baker H. Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency. Cell Stem Cell. 2014;14(5):592–605.View ArticlePubMedPubMed CentralGoogle Scholar
- Lehmann S, Te Boekhorst V, Odenthal J, Bianchi R, van Helvert S, Ikenberg K, Ilina O, Stoma S, Xandry J, Jiang L, et al. Hypoxia Induces a HIF-1-dependent transition from collective-to-amoeboid dissemination in epithelial cancer cells. Curr Biol. 2017;27(3):392–400.View ArticlePubMedGoogle Scholar
- Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE, Rich JN. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 2016;76(8):2465–77.View ArticlePubMedPubMed CentralGoogle Scholar
- Vordermark D, Shibata T, Brown JM. Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia. 2001;3(6):527–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Q, Lin Q, Yun Z. Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells. Cancer Biol Ther. 2016;17(12):1266–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000;7(6):493–8.View ArticlePubMedGoogle Scholar
- Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, Calvo V, Cheung JF, Bravo-Cordero JJ, Entenberg D, et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol. 2017;19(2):120–32.View ArticlePubMedPubMed CentralGoogle Scholar
- Le A, et al. Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter. Proc Natl Acad Sci USA. 2014;111(34):12486-91.Google Scholar
- Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689–721.View ArticlePubMedGoogle Scholar
- Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer. 2010;102(2):428–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, Denley H, Miller CJ, Homer JJ, Rojas AM, et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res. 2013;19(17):4879–88.View ArticlePubMedPubMed CentralGoogle Scholar
- Sorensen BS, Knudsen A, Wittrup CF, Nielsen S, Aggerholm-Pedersen N, Busk M, Horsman M, Hoyer M, Bouchelouche PN, Overgaard J, et al. The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. Radiother Oncol. 2015;116(3):346–51.View ArticlePubMedGoogle Scholar
- Koren S, Bentires-Alj M. Breast tumor heterogeneity: source of fitness, hurdle for therapy. Mol Cell. 2015;60(4):537–46.View ArticlePubMedGoogle Scholar
- Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16(3):225–38.View ArticlePubMedPubMed CentralGoogle Scholar
- Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.View ArticlePubMedGoogle Scholar
- Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN. Twisted tango: brain tumor neurovascular interactions. Nat Neurosci. 2011;14(11):1375–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee KE, Simon MC. From stem cells to cancer stem cells: HIF takes the stage. Curr Opin Cell Biol. 2012;24(2):232–5.View ArticlePubMedGoogle Scholar
- Semenza GL. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors. Clin Sci (Lond). 2015;129(12):1037–45.View ArticlePubMedGoogle Scholar
- Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol. 2012;13(1):e43–8.View ArticlePubMedGoogle Scholar
- Kapucuoglu N, Bozkurt KK, Baspinar S, Kocer M, Eroglu HE, Akdeniz R, Akcil M. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211(10):740–7.View ArticlePubMedGoogle Scholar
- Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64(11):937–46.View ArticlePubMedGoogle Scholar
- Kim HJ, Kim JB, Lee KM, Shin I, Han W, Ko E, Bae JY, Noh DY. Isolation of CD24(high) and CD24(low/−) cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Lett. 2007;258(1):98–108.View ArticlePubMedGoogle Scholar
- Kwon MJ, Han J, Seo JH, Song K, Jeong HM, Choi JS, Kim YJ, Lee SH, Choi YL, Shin YK. CD24 overexpression is associated with poor prognosis in luminal A and triple-negative breast cancer. PLoS One. 2015;10(10):e0139112.View ArticlePubMedPubMed CentralGoogle Scholar
- Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L. The clinicopathologic and prognostic significance of CD44+/CD24(−/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol. 2008;39(7):1096–102.View ArticlePubMedGoogle Scholar
- Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331–45.View ArticlePubMedGoogle Scholar
- Moerkens M, Zhang Y, Wester L, van de Water B, Meerman JH. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014;14:283.View ArticlePubMedPubMed CentralGoogle Scholar
- Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1(9):707–17.PubMedGoogle Scholar
- Perez-Tenorio G, Stal O. Southeast Sweden Breast Cancer G. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002;86(4):540–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154–66.View ArticlePubMedPubMed CentralGoogle Scholar
- D'Angelo RC, Wicha MS. Stem cells in normal development and cancer. Prog Mol Biol Transl Sci. 2010;95:113–58.View ArticlePubMedGoogle Scholar
- Voskas D, Ling LS, Woodgett JR. Signals controlling un-differentiated states in embryonic stem and cancer cells: role of the phosphatidylinositol 3′ kinase pathway. J Cell Physiol. 2014;229(10):1312–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050–60.View ArticlePubMedGoogle Scholar
- Carcereri de Prati A, et al. Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia. J Cell Biochem. 2017;118(10):3237-48.Google Scholar
- Iriondo O, Rabano M, Domenici G, Carlevaris O, Lopez-Ruiz JA, Zabalza I, Berra E, Vivanco M. Distinct breast cancer stem/progenitor cell populations require either HIF1alpha or loss of PHD3 to expand under hypoxic conditions. Oncotarget. 2015;6(31):31721–39.View ArticlePubMedPubMed CentralGoogle Scholar
- Shiraishi A, Tachi K, Essid N, Tsuboi I, Nagano M, Kato T, Yamashita T, Bando H, Hara H, Ohneda O. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells. Cancer Sci. 2017;108(3):362–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen JW, Samanta D, Liang H, Semenza GL. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2014;5(24):12509–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X, Semenza GL. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. Proc Natl Acad Sci USA. 2016;113(14):E2047–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, Semenza GL. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016;7(40):64527–42.PubMedPubMed CentralGoogle Scholar
- Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, Gilkes DM, He J, Semenza GL. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci USA. 2015;112(45):E6215–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 2012;109(8):2784–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991;51(12):3316–22.PubMedGoogle Scholar
- Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res. 2007;9(3):303.View ArticlePubMedPubMed CentralGoogle Scholar
- Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73.View ArticlePubMedGoogle Scholar
- Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, Koritzinsky M, Kasprzyk A, Boutros PC, Wouters BG, et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother Oncol. 2012;102(3):436–43.View ArticlePubMedGoogle Scholar
- Vaupel P, Briest S, Hockel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr. 2002;152(13–14):334–42.View ArticlePubMedGoogle Scholar